51 results about "Devergie's disease" patented technology

Devices, systems and methods are disclosed that allow a patient to self-treat neurodegenerative diseases, such as dementia, Alzheimer's disease, ischemic stroke, post-concussion syndrome, chronic traumatic encephalopathy and the like by electrical noninvasive stimulation of a vagus nerve. The system comprises a handheld stimulator that is applied to the surface of the patient's neck, wherein the stimulator comprises or is joined to a smartphone. A camera of the smartphone may be used to position and reposition the stimulator to a particular location on the patient's neck. The system may also comprise a base station that is used to meter the charging of a rechargeable battery within the stimulator. The base station and stimulator transmit data to one another regarding the status of a stimulation session.

Disclosed are methods and systems and methods for non-invasive neuromodulation using ultrasound for the Treatment of Autism Spectrum Disorders and Alzheimer's Disease and other dementias. The neuromodulation can produce acute or long-term effects. The latter occur through Long-Term Depression (LTD) and Long-Term Potentiation (LTP) via training. Included is control of direction of the energy emission, intensity, frequency, pulse duration, firing pattern, and phase / intensity relationships to targeting and accomplishing up regulation and / or down regulation.

A method for the treatment and prophylaxis of conditions of aging in humans, such conditions of aging associated with a decreased presence of cell-specific carbonic anhydrase enzymes in the brain, such as conditions associated with chronic neurodegenerative conditions including dementia such as Alzheimer's disease, which method includes the administering over an extended period of time, ranging from 6 months to 5 years, of a pharmaceutically effective, non-toxic amount of a compound that increases the presence of cell-specific carbonic anhydrase enzymes in the brain. That compound may be the cell-specific carbonic anhydrase enzyme, a compound that when absorbed by the body reacts or dissociates to form the cell-specific carbonic anhydrase enzyme, or a compound that promotes the natural generation of the cell-specific carbonic anhydrase enzyme within the body.

The present invention discloses a use of silymarin in preparations of drugs for prevention or treatment of Alzheimer's disease, and belongs to the field of medicine. When silymarin is used for treatment or prevention of human or mammalian Alzheimer's diseases, the silymarin can be adopted as the drug separately, and can further be combined with other drugs for treatment of Alzheimer's disease, wherein action mechanisms of other drugs for treatment of Alzheimer's disease are different to the action mechanism of the silymarin, and the drug combination can provide effects of reducing of toxic and side effects of drugs and synergistic therapeutic effect. The silymarin can significantly inhibit beta amyloid deposition, and provides definite therapeutic effect and low side effects for prevention or treatment of Alzheimer's disease so as to provide broad medicine application prospects.

The invention discloses a Chinese medicinal formulation for preventing and treating senile dementia and a production method thereof. The invention is characterized in that the Chinese medicinal formulation is made from the following Chinese medicinal raw materials in parts by weight: 3-15 of Arillus longan pulp, 3-15 of Polygonum multiflorum and 3-15 of mulberry. The Chinese medicinal formulation has the effects of tonifying the kidney-essence, promoting blood circulation, removing blood stasis, nourishing the heart, soothing the mind and regulating the activity of acetylcholinesterase in the brain cholinergic nerve system; and can be used for prevention and treatment of senile dementia, manifested by symptoms of amnesia, insomnia, hypomnesia and change of activity of brain acetylcholinesterase (AchE) with good efficacy.

The invention belongs to the field of nutritional supplement agent type nutritive function food or medicine-food dual purposes, and relates to a nutritive combination agent capable of preventing and treating dementia. The nutritive combination agent capable of preventing and treating dementia is characterized by comprising powder of multiple plant extracts, an oiling agent and vitamins, is capable of providing essential nutrition and other substances for brain cells, promoting brain cells to absorb nutrition and exclude toxins very well, ensuring that brain cells and brain tissues accelerate own ability of regulation and control, and preventing symptoms such as memory loss and dementia and has a treatment effect for patients with senile dementia and parkinson disease and certain moderate and severe patients.

Methods, kits, screens, assays, treatments and treatment regimes for treating a patient at risk for or suffering from dementia, and particularly Alzheimer's dementia which are based upon identification of enhanced risk by genotyping APOE and APOJ. In particular, described herein are methods for the prophylactic treatment of dementia based upon results of said genotyping. The systems and methods herein described may be used both to detect and to target the primary genetically mediated pathways associated with amyloid burden. For example, a system for deciding treatment based on previously identified genetic polymorphisms (e.g., APOE4, polymorphism in APOJ) that affect amyloid clearance is described herein; such patients may respond to treatments that modulate glial based GLT-1 (e.g., Tianeptine) and / or enhance HSP expression / activity (e.g., GGA).

The invention discloses a medicine for preventing and treating senile dementia. The medicine is prepared by mixing 0.3-99.7 parts of industrial hemp semen cannabis extract and 0.3-99.7 parts of industrial hemp cannabinoid to be uniform. The pharmaceutical composition has an obvious relieving effect on spatial cognition disorder and study and memory function decline caused by senile dementia and cerebral ischemia, the content of inhibitory amino acid aspartic acid, glycine and gamma-aminobutyric acid on the cerebral cortex of a senile dementia rat can be increased, the toxicity of excitable glutamic acid can be reduced, generated beta-AP in AD rat hippocampus can be reduced, and an obvious relieving effect is achieved for memory function decline caused by cerebral ischemia; mouse dysmnesia caused by NaNO2 can be obviously relieved. All effects are superior to those of cannabidiol. The medicine has a definitely remarkable effect on preventing and treating senile dementia and has good application and popularization prospects.

The invention relates to the technical field of traditional Chinese medicines, and provides a traditional Chinese medicine decoction for treating senile dementia. The decoction is prepared from the following medicinal raw materials by weight: 20g of salvia miltiorrhiza, 20g of radix paeoniae rubra, 20g of angelica sinensis, 15g of dragon bone, 10g of ligusticum wallichii, 10g of radix achyranthis bidentatae, 10g of irkutsk anemone rhizome, 10g of chrysanthemum, 9g of arisaema cum bile, 9g of earthworm, 6g of rhizoma atractylodis macrocephalae, 6g of vermilion, 6g of licorice root, 10g of black sesame powder and 0.25g of pseudo-ginseng powder. The traditional Chinese medicine decoction has the functions of clearing away heart-fire, relieving restlessness, refreshing mind and tranquilizing, tonifying kidneys to promote generation of marrow and strengthening brain, and has a remarkably curative effect on treatment of senile dementia.

The orally taken medicine for treating dementia and hypophrenosis is prepared with 12 kinds of Chinese medicinal materials, including polygala root, grassleaved sweetflag rhizome, cassia twig, angelica, dry ginger, etc. in certain proportion. Initial clinical test shows that the orally taken medicine has obvious curative effect and no toxic side effect on heart, liver, kidney, blood system, etc. found. It may be used clinically after further test.

The invention discloses a fermented product of a fungi strain for treating dementia. The fungi strain is separated from endophytic fungi of Huperzia serrata and belongs to fusarium oxysporum NSG-1 strain. After the passage of 20 generations in laboratory, the fungi strain has genetic stability. The amino sequence of the fungi strain is as shown in SEQ ID NO:1. The fungi strain provided by the invention is used as a biologic strain for treating vascular dementia and senile dementia; the excellent high-efficiency expression gene for generating huperzine a is transferred into the strains in other modes; more excellent characteristics can be acquired through gene modification; besides, further optimization for the bacterial strain can be achieved through mutation breeding; the research on the fungi strain has huge significance in biosynthesis industrial production of huperzine a, plant resource protection, settlement for the clinic first-line pharmacy requirement and reduction of medical expense for treating vascular dementia and senile dementia patients.

The invention discloses a drug for treating senile dementia. The drug is formed by compatibility of the following pharmaceutical ingredients: 3-7 parts of ginseng, 5-15 parts of the fruit of Chinese wolfberry, 4-6 parts of cistanche, 5-12 parts of tuber of dwarf lilyturf, 4-12 parts of poria cocos, 3-8 parts of polygala tenuifolia, 5-9 parts of scutellaria baicalensis, 7-13 parts of sealwort, 1-3 parts of cordyceps sinensis, 4-8 parts of white atractylodes rhizome, 5-9 parts of spina date seed, 4-9 parts of codonopsis pilosula, 2-6 parts of tortoise plastron, 2-5 parts of the root of bidentate achyranthes, 3-9 parts of human placenta, 4-12 parts of radix rehmanniae, and 4-12 parts of rehmanniae vaporata. The drug disclosed by the invention is prepared by sterilizing the above drugs, drying through a dryer, crushing into 600-mesh through a crusher and encapsuling powder. All the drugs in the invention are natural pure traditional Chinese medicines; found from clinical verification, after being taken, the drug has the obvious effect for treating senile dementia; furthermore, the drug is free from any side effect; and patients cannot have drug dependence.

The invention discloses a system method for using an APP to provide all-round services to Alzheimer's patients, including: A, location tracking: find the location of a locator installed on a patient through an APP on a mobile terminal, and track the patient's movement track; B, Interactive popularization of disease knowledge: configure the information publicity platform, receive publicity information input by specific users on the platform, and publish the received information on the information publicity platform of the app, including reporting the latest research trends on Alzheimer's disease and popularizing Alzheimer's disease Common sense of Alzheimer's disease prevention, carry out nursing interaction of Alzheimer's disease, provide dietary conditioning for Alzheimer's disease patients, provide communication and interaction between family members of Alzheimer's disease patients; be able to carry out effective disease communication and mutual Nursing; 3. Under the scientific guidance of neurologists, professional medical guidance can be obtained to help patients' families take better care of patients.

Compositions containing one or more kinds of essential amino acids other than leucine and not less than 35 mol % of leucine, relative to the total content of essential amino acids, are useful for preventing or improving dementia or a depressive state, in particular, a depressive state caused by stress, have high safety, and can be continuously ingested or administered.

The present invention refers to the use of a specific indolocarbazole compound of general formula (1) or a pharmaceutically-acceptable a salt thereof for the preparation of a pharmaceutical composition for the prevention or treatment of a neurode-generative and / or dementing illness driven by the molecular pathology of microtubule-associate tau such as Alzheimer's disease, frontal lobe dementia, Pick's disease, Parkinson disease with dementia, corticobasal degeneration, argyrophilic grains disease, or supranuclear palsy. A method for treating or preventing such illnesses is also disclosed. Furthermore, methods for the identification of efficacious inhibitors of neurofibrillary degeneration, and methods for the determination of an appropriate dosage of an inhibitor of the PHF-type tau hyperphosphorylation for the treatment of a condition characterized by neurofibrillary pathology are described.

The invention discloses application of a semen aesculi extract to preparation of a medicine and a health-care product for preventing and treating senile dementia, wherein the active component of the semen aesculi extract is beta-aescin. According to experiments, the traditional Chinese medicine semen aesculi extract can obviously improve dysmnesia of model animals and improve the learning capability, can effectively improve and adjust central cholinergic nerve as well as adjust free radical metabolism, and has exact curative effect on various kinds of senile dementia such as Alzheimer's disease, vascular dementia and mixed dementia.

The invention provides application of a medicament composition in preparing a medicament for preventing or treating senile dementia, wherein the medicament composition is prepared by processing herba hyperici perforate and acanthopanax root, and adding auxiliary materials acceptable pharmaceutically into various dosage forms. The pharmacological research shows that the composition plays the certain role of preventing and treating senile dementia, and obviously improves the learning disabilities and memory ability.

The invention provides a crude drug composition used for preventing or treating dementia or neurodegenerative diseases. The invention relates to a composition which contains pseudo-ginseng and Eucommia ulmoides as effective crude drug components and is used for preventing or treating dementia or behavior and psychological symptoms thereof or neurodegenerative diseases. The invention also relates to a composition which contains pseudo-ginseng, Eucommia ulmoides and Rhizoma Polygonatum as effective crude drug components and is used for preventing or treating dementia or behavior and psychological symptoms thereof or neurodegenerative diseases. The invention also relates to a composition which contains pseudo-ginseng, Eucommia ulmoides, Rhizoma Polygonatum and Radix Glycyrrhizae and is used for preventing or treating dementia or behavior and psychological symptoms thereof or neurodegenerative diseases.

The present invention provides a therapeutic agent for dementia comprising a pharmaceutically active substance derived from Hericium ramosum.

The invention relates to an area of the chemical-pharmaceutical industry and medicine, particularly to an agent for treatment of dementias, including Alzheimer's disease (AD), as well as to a method of treatment and pharmaceutical composition, which is effective for both treatment of dementias, including AD or dementias of Alzheimer type, and during manifestations of the first symptoms of memory disorder.The given invention consists of the development of a new therapeutic substance with minimal side effects that currently is a topical issue for treatment of the corresponding diseases.Attached is the use of polyprenols of formula (1)where n=8-20 as an active ingredient for the production of the therapeutic agent for the treatment of patients with dementia syndrome, including those who suffer from Alzheimer's disease.It is proposed to use a therapeutic agent for the treatment of patients with dementia syndrome, including those suffering from Alzheimer's disease, being polyprenols of formula (1).It was proposed that a pharmaceutical composition for the treatment of patients suffering from dementia syndrome, including patients suffering from Alzheimer disease, being an effective amount of polyprenols of formula (1) and pharmaceutically acceptable additional substances, including carriers and / or solvents, additives and / or lubricants.It was proposed that a method for treatment of patients suffering from dementia syndrome, including patients suffering from Alzheimer's disease, when effective amount of polyprenols of formula (1) is administered in the form of the substance or as a pharmaceutical composition that includes additional components.

The invention discloses a medicine composition for treating the Alzheimer's disease. The medicine composition is prepared from, by weight, 10-50 parts of eleutherococcus senticosus and 7-56 parts of lychee seed. According to the medicine composition, only two traditional Chinese medical materials of the eleutherococcus senticosus and the lychee seeds are in compatibility and added into medicine, the ratio of the weight parts of the eleutherococcus senticosus and the lychee seeds are adjusted that the eleutherococcus senticosus has 10-50 parts and the lichee seeds have 7-56 parts, the eleutherococcus senticosus and the lychee seeds play the synergistic interaction effect, the treatment effect for treating the Alzheimer's disease is obvious, the components of the medicine composition are simple, the quality is easy to control, and the treatment effect is definite. The invention further provides a preparing method of the medicine composition, according to the preparing method, medicine active components in the medical materials of the eleutherococcus senticosus and the lychee seeds can be extracted effectively, and operation is simple. The invention further provides the application of the medicine composition in preparing medicine for relieving recognition memory dysfunctions.

This invention relates to the field of screening for, identifying, and diagnosing tangle-predominant dementia (TPD). Specifically, this invention provides various biomarkers for this disease, and methods of using these biomarkers to correctly subclassify patients with Alzheimer's-type dementia by differentiating TPD patients from those with classical Alzheimer's disease (AD), as well as prodromal AD, and mild cognitive impairment due to AD.

This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as conditions such as stroke-induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning. In a particular aspect, the invention relates to bicyclic amide compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.